UBE2T and melanoma: Previous studies have reported that UBE2T is overexpressed in several cancer types, such as melanoma, ovarian cancer, renal cancer and hepatocellular carcinoma, and its overexpression correlates with cancer progression and poor prognosis (16,37,38).